Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRD9 is essential for ribosome biogenesis and survival of multiple myeloma cells.

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE197492 | GEO | 2023/02/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Multiple myeloma

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-01-24 | GSE125364 | GEO

Post-transcriptional regulation of Ribosome Biogenesis

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-08-03 | GSE231980 | GEO

Multiple mechanisms disrupt let-7 miRNA biogenesis and function in neuroblastoma

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-07-06 | E-GEOD-81500 | biostudies-arrayexpress

The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis.

Project description:The orphan small nucleolar RNA (snoRNA) ACA11 is overexpressed as a result of the t(4;14) chromosomal translocation in multiple myeloma (MM), increases reactive oxygen species, and drives cell proliferation. Like other snoRNAs, ACA11 is predominantly localized to a sub-nuclear organelle, the nucleolus. We hypothesized that increased ACA11 expression would increase ribosome biogenesis and protein synthesis. We found that ACA11 overexpression in MM cells increased nucleolar area and number as well as silver-binding nucleolar organizing regions (AgNORs). Supporting these data, samples from t(4;14)-positive patients had higher AgNORs scores than t(4;14)-negative samples. ACA11 also upregulated ribosome production, pre-47S rRNA synthesis, and protein synthesis in a ROS-dependent manner. Lastly, ACA11 overexpression enhanced the response to proteasome inhibitor in MM cells, while no effect was found in response to high doses of melphalan. Together, these data demonstrate that ACA11 stimulates ribosome biogenesis and influences responses to chemotherapy. ACA11 may be a useful target to individualize the treatment for t(4;14)-positive myeloma patients.

| S-EPMC6996358 | biostudies-literature

Post-transcriptional regulation of Ribosome Biogenesis during differentiation

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-08-03 | GSE214875 | GEO

Multiple myeloma patients and control

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-10-06 | GSE159232 | GEO

Gene expression signature predicting post-relapse survival of myeloma patients identified by co-culture of myeloma cells with osteoclasts and osteoblast progenitors

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-08-13 | E-GEOD-31162 | biostudies-arrayexpress

p53 activation during ribosome biogenesis regulates normal erythroid differentiation.

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-09-14 | GSE157210 | GEO

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.

Project description:Bromodomain-containing protein 9 (BRD9), an essential component of the SWI/SNF chromatin remodeling complex termed ncBAF, has been established as a therapeutic target in a subset of sarcomas and leukemias. Here, we used novel small molecule inhibitors and degraders along with RNA interference to assess the dependency on BRD9 in the context of diverse hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM) model systems. Following depletion of BRD9 protein, AML cells undergo terminal differentiation, whereas apoptosis was more prominent in ALL and MM. RNA-seq analysis of acute leukemia and MM cells revealed both unique and common signaling pathways affected by BRD9 degradation, with common pathways including those associated with regulation of inflammation, cell adhesion, DNA repair and cell cycle progression. Degradation of BRD9 potentiated the effects of several chemotherapeutic agents and targeted therapies against AML, ALL, and MM. Our findings support further development of therapeutic targeting of BRD9, alone or combined with other agents, as a novel strategy for acute leukemias and MM.

| S-EPMC9296512 | biostudies-literature

Multiple myeloma tumors from Vk*MYC mice

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-02-20 | GSE111922 | GEO